Neugenesis in the News
THERAPEUTIC MONOCLONAL ANTIBODIES Novel Routes to Mabs |
February 1, 1998 issue
Visit GEN
Neugenesis Corp. (Honolulu, HI) has demonstrated three novel techniques for producing therapeutic antibodies. The firm's gene-shuffling technology operates within the cell rather than from outside. Neugenesis expects this approach to induce cells to produce improved genes coding for disease-specific therapeutic Mabs.
Neugenesis' second, patented technology mixes and matches subunits of heteromeric molecules to create panels of combinatorial libraries of all possible subunit combinations. From these panels, effective new combinations of subunit variants can be easily selected. IgG monoclonals, with their kappa and gamma subunits, are the first targets for this system. The last approach produces intact IgG molecules from fused strains of Neugenesis's primary host cell, Neurospora crassa.